RA Capital Management 13F holdings, Q3 2008
Holdings as of September 30, 2008 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 20 US equity positions worth $329.1m in its Q3 2008 13F filing. The largest position was SEQUENOM INC at 64.7% of the reported book, followed by QUESTCOR PHARMACEUTICALS INC and ONYX PHARMACEUTICALS INC. Against the Q2 2008 filing, it opened 4 new positions, added to 6 and reduced 5 among the top 20 holdings.
What did RA Capital Management own in Q3 2008? Top 20 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2008 |
|---|---|---|---|---|---|---|---|
| 1 | SEQUENOM INC | 64.7% | $213.1m | 8,005,580 | 36% | added | |
| 2 | QUESTCOR PHARMACEUTICALS INC | 6.6% | $21.7m | 2,958,230 | 3% | added | |
| 3 | ONYX PHARMACEUTICALS INC | 5.0% | $16.5m | 456,159 | 0% | held | |
| 4 | PHARMASSET INC | 4.7% | $15.6m | 781,071 | 0% | held | |
| 5 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 4.5% | $14.7m | 442,044 | 73% | added |
| 6 | JAVELIN PHARMACEUTICALS INC | 2.7% | $8.9m | 3,438,117 | -15% | reduced | |
| 7 | AMAG AMAG PHARMACEUTICALS INC | 2.6% | $8.4m | 216,780 | 0% | held | |
| 8 | OREXIGEN THERAPEUTICS INC | 2.0% | $6.7m | 617,608 | 22% | added | |
| 9 | CRIS CURIS INC | 2.0% | $6.5m | 5,614,764 | -2% | reduced | |
| 10 | ARDEA BIOSCIENCES INC | 1.9% | $6.4m | 461,609 | 4% | added | |
| 11 | ROCKWELL MEDICAL TECH | 1.3% | $4.2m | 1,014,922 | -26% | reduced | |
| 12 | ATHERSYS INC | 0.6% | $2.1m | 1,194,500 | -6% | reduced | |
| 13 | DYNAVAX TECHNOLOGIES CORP | 0.4% | $1.2m | 815,383 | 236% | added | |
| 14 | GENELABS TECHNOLOGIES INC | 0.3% | $1.1m | 2,520,153 | 0% | held | |
| 15 | SOMAXON PHARMACEUTICALS INC | 0.2% | $729.0k | 232,206 | -21% | reduced | |
| 16 | SUCAMPO PHARMACEUTICALS INC | 0.1% | $388.0k | 45,476 | – | new | |
| 17 | CHELSEA THERAPEUTICS INTL LT | 0.1% | $332.0k | 102,200 | – | new | |
| 18 | HANA BIOSCIENCES INC | 0.1% | $300.0k | 500,000 | 0% | held | |
| 19 | PROGEN PHARMACEUTICALS LIMIT | 0.1% | $280.0k | 500,000 | – | new | |
| 20 | CYTRX CORP | 0.0% | $115.0k | 225,896 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.